I should like to suggest that his study can be criticised merely on the grounds of the small size of his sample.

The only direct comparison of the figures for matched groups that he makes is that of the first-week mortality of babies with birthweights between 751 and 1000 g and gestational ages of less than 30 weeks, between his unit in Salisbury and that in UCH, London. There was no significant difference in mortality.

It is important, however to establish how high or how low the Salisbury mortality would have to be to show a statistically significant difference from that at UCH. It is possible to do this using a 2×2 contingency χ^2 test.

Keeping the UCH mortality figures for this group of babies and the total number in the same group at Salisbury constant, different proportions for the live and dead subgroups in Salisbury can be substituted.

Table Comparison of different possible levels of mortality at Salisbury, with the observed mortality at UCH

Observed mortality of 76%

	Lived	Died	Total
Salisbury	5	16	21
UCH	8	32	40

then $\chi^2 = 0.0003$, $P > 0.05$.

Hypothetical mortality of 52.4%

	Lived	Died	Total
Salisbury	10	11	21
UCH	8	32	40

then $\chi^2 = 3.8094$, $P > 0.05$.

Hypothetical mortality of 100%

	Lived	Died	Total
Salisbury	0	21	21
UCH	8	32	40

then $\chi^2 = 3.2381$, $P > 0.05$.

Out of a total of 21 babies in Salisbury, 16 died, a mortality of 76%. χ^2 for the observed figures compared with those at UCH is 0.0003, $P > 0.05$. If 11 out of the 21 babies in the Salisbury group had died, that is a mortality of 52.4%, then $\chi^2 = 3.8094$, $P > 0.05$. If all 21 Salisbury babies had died, a mortality of 100%, the $\chi^2 = 3.2381$, $P > 0.05$. So, with this sample size, a mortality in Dr Hughes-Davies's unit of anywhere between 53% and 100% would not have been significantly different at the 5% level from the results obtained at UCH.

In summary, it is possible to ignore any criticisms of the nature of the comparisons of mortality made by Dr Hughes-Davies. With this sample size, the range of mortality possible at Salisbury, without it differing significantly from the mortality at UCH, is so great as to make impossible any conclusions about the comparative merits of the methods of care.

I thank Professor Tizard for his help and encouragement.

References

- Hughes-Davies T H. Conservative care of the newborn baby. *Arch Dis Child* 1979; **54**: 59-61.
- Dunn P M, Speidel B D. Letter: Conservative care of the newborn baby. *Arch Dis Child* 1979; **54**: 482-4.
- Roberton N R C. Letter: Conservative care of the newborn baby. *Arch Dis Child* 1979; **54**: 484-5.

R C A PEARSON

Osler House Club,
Medical Students Common Room,
The Medical School Office,
John Radcliffe Hospital,
Headington, Oxford

Prostaglandin synthetase inhibitors and pulmonary hypertension

Sir,

In response to the paper by Wilkinson *et al.*¹ on persistent pulmonary hypertension in 3 neonates after maternal treatment with a prostaglandin synthetase inhibitor (naproxen) we describe twins who were exposed *in utero* to the largest recorded dose of indomethacin.

A 28-year-old gravida 2, para 1, had a Shiroadkar suture inserted during the 26th week of a twin pregnancy because of a dilating cervix. Continuing cervical dilatation and increased uterine activity resulted in the stitch cutting through the cervix despite venous infusion of beta sympathomimetics. The patient, a doctor who was aware of the potential side effects of prostaglandin synthetase inhibitors, was given indomethacin 100 mg rectally with immediate reduction in uterine activity and no further dilatation of the cervix. A total dose of 500 mg indomethacin was given rectally over 48 hours. Subsequently the patient treated herself with indomethacin 25 mg orally as required until the 35th week of the pregnancy. The total dose of indomethacin was 1900 mg.

Spontaneous rupture of the membranes and vaginal delivery of live boys weighing 3.09 kg and 2.69 kg occurred at 37 weeks. Both babies breathed spontaneously at birth and were pink in air at one minute. Examination showed no abnormality in the cardiovascular or respiratory system. At the age of 12 months they remain healthy.

We thank Mr P J Murphy and Dr D W Warrell for allowing us to report on their patient.

References

- Wilkinson A R, Aynsley-Green A, Mitchell M D. Persistent pulmonary hypertension and abnormal prostaglandin E levels in preterm infants after maternal treatment with naproxen. *Arch Dis Child* 1979; **54**: 942-5.

M J JOHNSTONE AND M L CHISWICK

St Mary's Hospital,
Whitworth Park,
Manchester M13 0JH